Identification of Novel Class of Triazolo-Thiadiazoles as Potent Inhibitors of Human Heparanase and their Anticancer Activity
作者:C. P. Baburajeev、Chakrabhavi Dhananjaya Mohan、Shobith Rangappa、Daniel J. Mason、Julian E. Fuchs、Andreas Bender、Uri Barash、Israel Vlodavsky、Basappa、Kanchugarakoppal S. Rangappa
DOI:10.1186/s12885-017-3214-8
日期:2017.12
screened, we identified 1,2,4-triazolo-1,3,4-thiadiazoles bearing compounds to possess human heparanase inhibitory activity. Further analysis revealed 2,4-Diiodo-6-(3-phenyl-[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-6yl)phenol (DTP) as the most potent inhibitor of heparanase enzymatic activity among the tested compounds. The inhibitory efficacy was demonstrated by a colorimetric assay and further validated
背景技术乙酰肝素酶(一种切割蛋白多糖的硫酸乙酰肝素(HS)侧链的内切糖苷酶)的表达和活性与许多癌症的进展和不良预后相关,这使其成为癌症治疗中有吸引力的药物靶标。方法在本工作中,我们报告了体外筛选150个小分子文库的方法,该文库带有喹诺酮,恶嗪,苯并恶嗪,异恶唑(二)酮,嘧啶酮,喹啉,苯并恶嗪和4-噻唑烷酮,噻二唑[3, 2-a]嘧啶-5-酮,1,2,4-三唑-1,3,4-噻二唑和氮杂螺环烷类化合物对人乙酰肝素酶的酶促活性具有抑制作用。使用培养的内皮细胞沉积的硫酸盐[35S]标记的细胞外基质(ECM)评估已鉴定的先导化合物的乙酰肝素酶抑制活性。进一步,评估了铅化合物对肝细胞癌(HepG2)和Lewis肺癌(LLC)细胞的抗侵袭效力。结果在筛选的150种化合物中,我们确定了带有人乙酰肝素抑制活性的1,2,4-三唑-1,3,4-噻二唑类化合物。进一步的分析表明,2,4-二碘-6-(3-苯基-[1